Wilson Disease Pipeline Analysis: 5+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight's, "Wilson Disease Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from Wilson Disease Pipeline Report
• DelveInsight's Wilson Disease Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Wilson Disease treatment.
• The leading Wilson Disease Companies such as Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, Ultragenyx Pharmaceutical, and others are evaluating novel Wilson Disease treatment drugs candidate to improve the treatment landscape.
• The promising Wilson Disease pipeline therapies in various stages of development include ALXN1840, SoC Therapy, Bis-Choline Tetrathiomolybdate, Trientine, TETA 4HCL, Penicillamine, NPC-02, and others.
• The companies and academics are working to assess challenges and seek opportunities that could influence Wilson Disease R&D. The therapies under development are focused on novel approaches to treat/improve Wilson Disease.

Get an overview of the Wilson Disease Pipeline landscape @ https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wilson Disease Overview
Wilson disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly the liver, brain, and corneas of the eyes. The disease is progressive and, if left untreated, it may cause liver (hepatic) disease, central nervous system dysfunction, and death. Common signs of associated liver disease include a yellow discoloration (jaundice) of the skin, mucous membranes and the membranes (sclera) that line the eye, swelling (edema) of the legs and abdomen (ascites). Wilson disease is inherited as an autosomal recessive trait. Wilson disease is caused by disruption or changes (mutations) of the ATP7B gene, which plays an important role in the movement of excess copper from the liver to the bile to eventually be excreted from the body through the intestines. Treatment for Wilson disease is life-long and aimed at lowering copper levels to nontoxic levels, and at preventing the progression of the disease and trying to reverse any signs and symptoms that have appeared because of copper accumulation in the body.

Latest Breakthroughs in the Wilson Disease Treatment Landscape
• ALXN1840 (bis-choline tetrathiomolybdate) is a novel oral copper-protein binding agent with a unique mechanism of action, under investigation for Wilson disease, a rare, chronic, genetic, and potentially life-threatening liver disorder of impaired copper transport. Enrollment of participants have been completed in a Phase 3 study of ALXN1840 in Wilson disease. The study results are expected in the first half of 2022.
• Triethylenetatramine (TETA) is a highly selective divalent Cu(II) chelator and a drug that revereses copper overload in tissues. Trientine is a copper chelator used in the treatment of Wilson's disease as an alternative to D-penicillamine. Clinical trials for TETA 4HCL are being carried out in phase III stage of development for the treatment of Wilsons disease.
Wilson Disease Emerging Drugs
• ALXN1840: Alexion Pharmaceuticals
• TETA 4HCL: Orphalan

Get to know more information about Wilson Disease treatment therapies @ https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wilson Disease Pipeline Therapeutics Analysis
There are approx. 5+ key companies which are developing the therapies for Wilson Disease. The companies which have their Wilson Disease drug candidates in the most advanced stage, i.e. phase III include, Alexion Pharmaceuticals.

DelveInsight's Wilson Disease Pipeline Report covers around 5+ products under different phases of clinical development like-
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Discover more about therapy set to grab substantial Wilson Disease Pipeline landscape @ https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Wilson Disease Pipeline Report
• Coverage- Global
• Wilson Disease Companies- Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, Ultragenyx Pharmaceutical, and others.
• Wilson Disease Therapies- ALXN1840, SoC Therapy, Bis-Choline Tetrathiomolybdate, Trientine, TETA 4HCL, Penicillamine, NPC-02, and others
• Wilson Disease Pipeline Assessment by Product Type
• Wilson Disease Pipeline Assessment by Stage and Product Type
• Wilson Disease Pipeline Assessment by Route of Administration
• Wilson Disease Pipeline Assessment by Stage and Route of Administration
• Wilson Disease Pipeline Assessment by Molecule Type
• Wilson Disease Pipeline Assessment by Stage and Molecule Type

Table of content
1. Introduction
2. Executive Summary
3. Wilson Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wilson Disease - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Wilson Disease Collaboration Deals
9. Late-Stage Products (Preregistration)
10. ALXN1840: Alexion Pharmaceuticals
11. Mid-Stage Products (Phase II)
12. Bis-Choline Tetrathiomolybdate: Alexion Pharmaceuticals
13. Early Stage Products (Phase I)
14. VTX-801: Vivet Therapeutics
15. Preclinical Stage Products
16. Drug Name: Company name
17. Inactive Products
18. Wilson Disease Key Companies
19. Wilson Disease Key Products
20. Wilson Disease- Unmet Needs
21. Wilson Disease- Market Drivers and Barriers
22. Wilson Disease- Future Perspectives and Conclusion
23. Wilson Disease Analyst Views
24. Wilson Disease Key Companies
25. Appendix

Got Queries? Reach out for more information on the Wilson Disease Pipeline Report @ https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.